Drugdiscovery >> Drugs >> News
4721
Views
Revlimid, a promising drug for asymptomatic myeloma? - drugdiscovery.com
Revlimid, a promising drug for asymptomatic myeloma? - drugdiscovery.com


The myeloma community has been encouraged by a new study of Celgene Corp's Revlimid which shows its effectiveness in patients whose disease has not yet progressed.
Read More >>


Tags: Revlimid, asymptomatic smouldering multiple myeloma - August 3, 2013
Related Articles
4004
Views
No Revlimid for chronic lymphocytic leukemia No Revlimid for chronic lymphocytic leukemia
Due to significant safety concerns, FDA halts clinical trial of this drug for chronic lymphocytic leukemia in patients 65 years and older. Read More >>

Tags: Revlimid, lenalidomide, lymphocytic leukema, drug safety

12252
Views
New drug for treating myeloma approved in Europe New drug for treating myeloma approved in Europe
The European Commission has granted approval for Celgene’s drug pomalidomide for the treatment of relapsed and refractory multiple myeloma, in combination with dexamethasone. The marketing name of Read More >>

Tags: Celgene, pomalidomide, multiple myeloma,Imnovid,the European Commission approval

4821
Views
Celgene’s cancer drug Imnovid may cause birth defects Celgene’s cancer drug Imnovid may cause birth defects
Imnovid (pomalidomide) has recently been approved in Europe for the treatment of adult patients with relapsed and refractory multiple myeloma (MM). Recent observations in animal models suggest that th Read More >>

Tags: imnovid, pomalidomide, teratogenic effect, multiple myeloma, warning, birth defects

7249
Views
The most promising drugs in biopharma's  late-stage pipeline The most promising drugs in biopharma's late-stage pipeline
An expert’s opinion on which are the 10 most prospective drugs in the late-stage pipeline at this moment. Read More >>

Tags: top 10, most promising, drugs, prospective, biopharma, pipeline

5856
Views
The most promising experimental cancer drugs-2013 The most promising experimental cancer drugs-2013
An expert’s opinion on the 10 most prospective experimental cancer drugs in 2013. Read More >>

Tags: top 10, experimental drugs, cancer, prospective, promising, cancer drugs, experimental

7023
Views
Velcade approved as a first line therapy in EU Velcade approved as a first line therapy in EU
Johnson & Johnson's multiple myeloma treatment Velcade (bortezomib) has been used in advanced patients and those who were ineligible for stem cell transplantation. In the future, it will also be used Read More >>

Tags: Velcade, multiple myeloma, Johnson & Johnson, approval, EC, EU

6458
Views
Zerenex, a promising drug for treating chronic kidney disease Zerenex, a promising drug for treating chronic kidney disease
Keryx Biopharmaceuticals has submitted a New Drug Application to the FDA. The drug is iron-based phosphate binder Zerenex, which showed impressive results in a phase III trial in treating elevated s Read More >>

Tags: Keryx Biopharmaceuticals, Zerenex, chronic kidney disease

6444
Views
New Drug Application for Delcath's drug rejected New Drug Application for Delcath's drug rejected
The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Delcath Systems’ drug MelblezTM Kit, for the treatment of patients with unresectable ocular melanoma Read More >>

Tags: new drug application, NDA, Delcath, ocular melanoma, drug, Melblez, melphalan

8526
Views
SOLIAIR™: New Respiratory Diseases Drug Discovery! SOLIAIR™: New Respiratory Diseases Drug Discovery!
SOLIAIR™ is a food supplement which has reported beneficial impact. Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. The SOLIAIR™ is free of side eff Read More >>

Tags: Drug Development,Drug Discovery,Medicine Development,COPD Treatment,Asthma Solution,Bronchitis Therapy,Respiratory Diseases,Lung Infections,Breathing Disorders,healthcare investment,Drug Innovation,

13685
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013